MedTrace Logo

Cannabis Observational Study on Mood, Inflammation, and Cognition

NCT03522103 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 421

Last updated 2021-07-12

No results posted yet for this study

Summary

This project examines the effects of cannabis on cognition and other domains of function and whether those effects are dependent upon the ratio of THC to CBD in the product. Current cannabis users are asked to stop using their typical product and to use cannabis containing different ratios of the cannabinoids THC and CBD. Participants complete baseline assessments including cognitive tasks, clinical measures, substance use history, and blood draw. Participants then acquire and use their study strain on their own, and after a period of use the mobile pharmacology laboratory goes to a location of their choosing. They complete cognitive, motor and blood-based assessments, then leave the mobile lab to use their study product one last time, returning to the mobile lab to complete cognitive, motor, and blood-based assessments immediately after use and one hour after use. A small subset of participants complete all of these procedures but use edible as opposed to flower-based products.

Conditions

Sponsors & Collaborators

  • University of Colorado, Boulder

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Kent Hutchison, PhD · University of Colorado, Denver

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2020-12-15
Completion
2020-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03522103 on ClinicalTrials.gov